ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1450

Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients

Patricia Bogas1, Chamaida Plasencia-Rodriguez1, Alejandro Balsa1, Dora Pascual-Salcedo2, Gema Bonilla1, Enrique Moral Coro1, Carolina Tornero1, Laura Nuño1, Diana Peiteado3, Ana Martínez4 and Borja Hernández1, 1Hospital Universitario La Paz, Madrid, Spain, 2Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, 3Rheumatology, La Paz University Hospital, Madrid, Spain, 4Immuno-Rheumatology research group, La Paz University Hospital, MADRID, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Anti-TNF therapy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: There is currently no consensus on selecting a therapeutic target in patients (pts) non-responsive to their first TNF inhibitors (TNFi). The development of anti-drug antibodies (ADA) is a frequent cause of secondary inefficacy in our pts with TNFi and there is evidence that those who develop ADA at their 1st TNFi achieve a higher degree of response to the second one, compared to ADA- pts. Thus ADA measurement can help in choosing a therapeutic target in pts who failed to respond to their 1st TNFi. The objective of this study was to assess if development of ADA to the 1st TNFi determines better response when switching to a 2nd TNFi versus a nonTNFi. As secondary objective, it was analyzed whether the presence or absence of ADA to a 1st TNFi influences the efficacy of a 2nd TNFi

Methods: Of a total of 110 pts that switched from infliximab or Adalimumab to a 2nd biologic agent (Etanercept, Rituximab, Tocilizumab, Adalimumab, Abatacept, Certolizumab and Infliximab), only 60, who had measured drug levels (DL)/ADA at discontinuation of the 1st TNFi, were included. Clinical response was evaluated with DAS28, Delta-DAS28 (ΔDAS28) and EULAR response (E-resp) at 6 (v-6) and 12 (v-12) months after initiating 2nd biologic agent and at the last visit prior to drug discontinuation or ending of the study for those who did not interrupt the biological therapy (v-end). DL/ADA levels were measured by ELISA. T tests and Fisher’s exact test were used to test statistical differences. Analysis was performed using SPSS version 20.0

Results: Within the 60 pts who had measured DL/ADA at suspension of the 1st TNFi, 26 (43%) were ADA-. In this ADA- subpopulation, 50% changed to a 2nd TNFi; at v-6 there were no differences between switchers to a 2nd TNFi and switchers to a nonTNFi in DAS28 (3.7±2.1 TNFi vs 4.2±1.1 nonTNFi, p=0.286), ΔDAS28 (1,4±2 TNFi, 1±1,2 nonTNFi, p=0,374) and resp-E (75% good/moderate resp in TNFi, 40% in nonTNFi, p=0,064). At v-12, switchers to a 2nd TNFi showed a lower DAS28 (2.5±0.6 TNF-i, 3.9±0.9 nonTNFi, p=0.009) and a higher good E-resp rate with a marginally significant difference (80% in TNFi, 22% in nonTNFi, p=0.071). However, at v-end, pts with a 2nd nonTNFi had better response (DAS28 > 5,1 in 50% of TNFi pts, 0% of nonTNFi, p=0.044). Likewise ΔDAS28 at v-end was higher in the nonTNFi group (0,7±1,7 TNFi, 1,7±0,8 nonTNFi, p=0,06). Along these lines, the good/moderate E-resp rate was higher in switchers to a nonTNFi (30% in TNFi, 92% in nonTNFi, p=0.006). In ADA+ subpopulation (n=34), no differences were found at v-end in DAS28 (3.7 ± 1.2 TNF-i, 3.9±1.1 nonTNFi, p=0.64), ΔDAS28 (0,63±1,6 in TNFi, 1,4±1,4 in nonTNFi, p=0,35) and good/moderate E-resp rate (65% in TNFi, 75% in nonTNFi, p=0,703). In pts who changed to a 2nd TNFi, those with ADA to 1st TNFi had a higher good response rate than ADA- pts (65% in ADA +, 30% in ADA-, p=0.07).

Conclusion: The development of ADA to the first TNFi entails a better response when switching to a 2nd TNFi, with a similar efficacy to the pts who switched to a nonTNFi. In those pts who did not develop immunogenicity to the 1st TNFi, there is a better response when changing therapeutic target. The ADA measurement can help to select the pts who can benefit from a 2nd TNFi.


Disclosure: P. Bogas, None; C. Plasencia-Rodriguez, None; A. Balsa, None; D. Pascual-Salcedo, None; G. Bonilla, None; E. Moral Coro, None; C. Tornero, None; L. Nuño, None; D. Peiteado, None; A. Martínez, None; B. Hernández, None.

To cite this abstract in AMA style:

Bogas P, Plasencia-Rodriguez C, Balsa A, Pascual-Salcedo D, Bonilla G, Moral Coro E, Tornero C, Nuño L, Peiteado D, Martínez A, Hernández B. Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/influence-of-immunogenicity-to-the-first-anti-tnf-therapy-on-response-to-the-second-biologic-agent-in-ra-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influence-of-immunogenicity-to-the-first-anti-tnf-therapy-on-response-to-the-second-biologic-agent-in-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology